Summary
Benitec Biopharma Ltd (Benitec), is a research based clinical stage biotechnology company. The company develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary gene silencing DNA directed RNA interference (ddRNAi) technology. It develops ddRNAi based therapeutics for various conditions such as hepatitis B, wet age related macular degeneration and OPMD. The company also licenses its ddRNAi to various biopharmaceutical companies for the development of drugs for the treatment of conditions such as HIV/AIDS, Huntington's disease, chronic neuropathic pain, cancer immunotherapy and retinitis. The company has its research laboratories in Hayward, California, the US. Benitec is headquartered in Sydney, New South Wales, Australia.
Benitec Biopharma Ltd (BLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Benitec Biopharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Benitec Biopharma Acquires Rights to Hepbarna from Biomics 13
Partnerships 14
Benitec Biopharma to Enter into Research Agreement with NantVentures 14
ReNeuron Enters into Research Agreement with Benitec Biopharma 14
Benitec Biopharma Enters Into An Agreement With Stanford University 15
Licensing Agreements 16
Benitec Biopharma Enters into Licensing Agreement with Nant Capital 16
Benitec Biopharma Enters into Licensing Agreement with Asklepios BioPharma 17
Benitec Biopharma Enters into Option for License Agreement with Touchlight Genetics for doggybone DNA 18
Benitec Biopharma Enters into Licensing Agreement with 4D Molecular Therapeutics 18
Benitec Biopharma Enters into Licensing Agreement with Circuit Therapeutics 19
Benitec Biopharma Enters Into Licensing Agreement With University of New South Wales For Tribetarna 20
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 21
uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology 22
Benitec Biopharma Enters Into Licenising Agreement With uniQure 23
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 24
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 25
Equity Offering 26
Benitec Biopharma Raises USD4.11 million in Private Placement of Shares 26
Benitec Biopharma Raises USD13.8 Million in Public Offering of ADS 27
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$28 Million 29
Benitec Biopharma Completes Rights Offering Of Shares For US$2.7 Million 30
Benitec Biopharma Completes Private Placement Of Shares For US$7 Million 31
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$7.2 Million 32
Benitec Biopharma Completes Private Placement Of Shares For US$0.2 Million 33
Benitec Biopharma Completes Private Placement Of Shares For US$0.8 Million 34
Benitec Completes Rights Issue Of US$8.45 Million 35
Acquisition 36
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To US$1.2 Million 36
Benitec Biopharma Ltd - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
May 24, 2016: Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016 41
Feb 26, 2016: Benitec Biopharma : Interim Report for the Half Year Ended December 31, 2015 42
Corporate Communications 43
Aug 10, 2016: Benitec announces restructuring of Senior Executive team 43
Government and Public Interest 44
Dec 22, 2016: Benitec Biopharma Provided A Market Update 44
Product News 45
Apr 21, 2016: Benitec to present data on muscular dystrophy program at the ASGCT 2016 Annual Meeting 45
Apr 21, 2016: Benitec to present data on hepatitis B program at the ASGCT 2016 Annual Meeting
Apr 21, 2016: Benitec to present data on hepatitis C program at the ASGCT 2016 Annual Meeting
Mar 08, 2016: Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo 48
Product Approvals 49
Jan 17, 2017: Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy 49
Clinical Trials 50
Apr 04, 2017: Key pre-clinical data on oculopharyngeal muscular dystrophy published in Nature Communications 50
Other Significant Developments 51
Jun 16, 2016: Benite Biopharma: Federal R&D Tax Credit Received 51
Apr 29, 2016: Benitec Biopharma: Quarterly Cash Flow–Appendix 4C 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Tables
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Benitec Biopharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Benitec Biopharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Benitec Biopharma Acquires Rights to Hepbarna from Biomics 13
Benitec Biopharma to Enter into Research Agreement with NantVentures 14
ReNeuron Enters into Research Agreement with Benitec Biopharma 14
Benitec Biopharma Enters Into An Agreement With Stanford University 15
Benitec Biopharma Enters into Licensing Agreement with Nant Capital 16
Benitec Biopharma Enters into Licensing Agreement with Asklepios BioPharma 17
Benitec Biopharma Enters into Option for License Agreement with Touchlight Genetics for doggybone DNA 18
Benitec Biopharma Enters into Licensing Agreement with 4D Molecular Therapeutics 18
Benitec Biopharma Enters into Licensing Agreement with Circuit Therapeutics 19
Benitec Biopharma Enters Into Licensing Agreement With University of New South Wales For Tribetarna 20
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 21
uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology 22
Benitec Biopharma Enters Into Licenising Agreement With uniQure 23
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 24
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 25
Benitec Biopharma Raises USD4.11 million in Private Placement of Shares 26
Benitec Biopharma Raises USD13.8 Million in Public Offering of ADS 27
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$28 Million 29
Benitec Biopharma Completes Rights Offering Of Shares For US$2.7 Million 30
Benitec Biopharma Completes Private Placement Of Shares For US$7 Million 31
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$7.2 Million 32
Benitec Biopharma Completes Private Placement Of Shares For US$0.2 Million 33
Benitec Biopharma Completes Private Placement Of Shares For US$0.8 Million 34
Benitec Completes Rights Issue Of US$8.45 Million 35
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To US$1.2 Million 36
Benitec Biopharma Ltd, Key Competitors 38
Benitec Biopharma Ltd, Key Employees 39
Benitec Biopharma Ltd, Other Locations 40
Benitec Biopharma Ltd, Subsidiaries 40List of Figures
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Benitec Biopharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
